These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26097793)

  • 1. Intravenous Pharmacokinetics, Local Tolerability, and Hemolysis of an SBE7-β-Cyclodextrin Formulation of the Neurokinin-1 Receptor Antagonist Vestipitant.
    Brigandi RA; Russ SF; Petit C; Johnson B; Croy S; Hodsman P; Muller F
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):130-136. PubMed ID: 26097793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of sulfobutyl ether-β-cyclodextrin (Captisol™) in Vestipitant IV solution by liquid chromatography with ultraviolet (UV) detection.
    Caltabiano AM
    J Pharm Biomed Anal; 2016 Jan; 118():276-283. PubMed ID: 26580825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S; De Smedt F; Toublanc N; Otoul C; Boulanger P; Riethuisen JM; Stockis A
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of intravenous sulfobutylether7 -β-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds.
    Leong NJ; Prankerd RJ; Shackleford DM; Mcintosh MP
    J Pharm Sci; 2015 Apr; 104(4):1492-8. PubMed ID: 25573540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
    Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
    Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
    Azuma J; Fukase H
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdominal laparoscopic surgery.
    Wininger SJ; Miller H; Minkowitz HS; Royal MA; Ang RY; Breitmeyer JB; Singla NK
    Clin Ther; 2010 Dec; 32(14):2348-69. PubMed ID: 21353105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro.
    Nagase Y; Hirata M; Arima H; Tajiri S; Nishimoto Y; Hirayama F; Irie T; Uekama K
    J Pharm Sci; 2002 Nov; 91(11):2382-9. PubMed ID: 12379923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
    Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
    Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
    Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads.
    Smith JS; Macrae RJ; Snowden MJ
    Eur J Pharm Biopharm; 2005 May; 60(1):73-80. PubMed ID: 15848059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial.
    Gan TJ; Gu J; Singla N; Chung F; Pearman MH; Bergese SD; Habib AS; Candiotti KA; Mo Y; Huyck S; Creed MR; Cantillon M;
    Anesth Analg; 2011 Apr; 112(4):804-12. PubMed ID: 21385988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
    Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
    J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study.
    Deloche C; Lopez-Lazaro L; Mouz S; Perino J; Abadie C; Combette JM
    Pharmacol Res Perspect; 2014 Feb; 2(1):e00020. PubMed ID: 25505576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a sulfobutyl ether beta-cyclodextrin as a solubilizing/stabilizing agent for several drugs.
    Ueda H; Ou D; Endo T; Nagase H; Tomono K; Nagai T
    Drug Dev Ind Pharm; 1998 Sep; 24(9):863-7. PubMed ID: 9876538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.